Latest News

• Natco Pharma announced the conclusion of the U.S. Food and Drug Administration (FDA) inspection at its Pharma Division in Kothur, Hyderabad, conducted from June 9th to June 19th, 2025.
• The company received 7 observations in Form-483 upon conclusion of the inspection.
• Natco Pharma is confident it will address the observations within the stipulated timeline and remains committed to cGMP compliance and supplying high-quality products.

• Natco Pharma Limited has appointed Mr. Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda.
• The appointment is effective from 16th June, 2025.
• Mr. Krishna Rao has over 33 years of experience in leading Indian Bulk Drug/API Manufacturing Industries, including 20 years as a Unit Head.
• He was previously associated with Dr. Reddy’s Laboratories Limited, Hyderabad, as Senior Director/Site Head - API manufacturing unit.

• The U.S. Food and Drug Administration (FDA) conducted an inspection at Natco Pharma's API manufacturing plant in Mekaguda, Hyderabad from 9 June 2025 to 13 June 2025.
• Natco Pharma received one observation in Form-483 upon conclusion of the inspection.
• The company believes the observation is procedural in nature and is confident in addressing it comprehensively.
• Natco Pharma remains committed to cGMP compliance and supplying high-quality products.

Natco Pharma Limited announced on 29th May 2025 that the audio recording of its earnings conference call for the quarter and year ended 31st March 2025 (FY24-25) has been uploaded on its website.

• The earnings call was held on 29th May 2025, at 11:00 Hrs IST.
• The audio recording is accessible at the following weblink: natcopharma.co.in/wp-content/uploads/2025/05/Q4FY25earningscall.mp3.
• This information is provided further to the company's intimation letter dated 20th May 2025.